Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | BLM | P54132 | 9/20 | 1.00 |
| ▸ | RECQL | P46063 | 8/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL319903 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL18926545 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL12863969 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL16923810 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL10079611 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL24914323 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL5941450 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL562720 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL22694307 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL6423269 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162934-A1 | COMPOSITIONS AND METHODS RELATING TO INHIBITING CANCER CELL GROWTH AND/OR PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-14 | — | — | US | disclosed |
| US-9745314-B2 | MDM2 inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-29 | — | — | US | disclosed |
| US-9618513-B2 | Compositions and methods for detecting and treating colorectal cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150299211-A1 | MDM2 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150212088-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING COLORECTAL CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-30 | — | — | US | disclosed |
| US-8680132-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-25 | — | — | US | disclosed |
| US-8518984-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-17 | — | — | US | disclosed |
| US-20090274773-A1 | ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT | CYCLACEL LIMITED (GB) | 2009-11-05 | — | — | US | disclosed |
| EP-1945265-A1 | ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT | Cyclacel Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007054731-A1 | ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20050222054-A1 | Combination comprising a CDK inhibitor and doxorubicin | CYCLACEL LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| EP-1487495-A1 | COMBINATION COMPRISING A CDK INHIBITOR AND DOXORUBICIN | Cyclacel Limited (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082337-A1 | COMBINATION COMPRISING A CDK INHIBITOR AND DOXORUBICIN | CYCLACEL LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299211-A1 | MDM2 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | TP53, MDM2, TP53BP1 | TOP2A 246/4885MEN1 2901/4885THRB 2851/4885 |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | TOP2A 139/4885MEN1 2954/4885THRB 795/4885 |
| US-20090274773-A1 | ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT | CCNI, CCNA2, CPT2 | TOP2A 8/4885MEN1 3032/4885THRB 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.